{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}],"units":"Participants"}],"description":"The number of participants who had any dose reductions or delays is presented.","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Number of Participants With Dose Reductions or Delays-Part 2","type":"PRIMARY","unitOfMeasure":"Participants"}